26.02.2013 Views

The role of eNOS, iNOS and NFκB in upregulation and activation of ...

The role of eNOS, iNOS and NFκB in upregulation and activation of ...

The role of eNOS, iNOS and NFκB in upregulation and activation of ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Abstract:<br />

Ye Y, et al. Mechanisms <strong>of</strong> COX2 <strong>upregulation</strong> by atorvastat<strong>in</strong> 2<br />

Objectives: Pretreatment with atorvastat<strong>in</strong> (ATV) reduces <strong>in</strong>farct size (IS) <strong>and</strong> <strong>in</strong>creases<br />

myocardial expression <strong>of</strong> phosphorylated endothelial nitric oxide synthase (P-<strong>eNOS</strong>),<br />

<strong>in</strong>ducible NOS (<strong>iNOS</strong>), <strong>and</strong> cycloxygenase-2 (COX2) <strong>in</strong> the rat. Inhibit<strong>in</strong>g COX2<br />

abolished the ATV-<strong>in</strong>duced IS limitation without affect<strong>in</strong>g P-<strong>eNOS</strong> <strong>and</strong> <strong>iNOS</strong> expression.<br />

We <strong>in</strong>vestigated: 1) whether 3-day ATV pretreatment limits IS <strong>in</strong> <strong>eNOS</strong> -/- <strong>and</strong> <strong>iNOS</strong> -/-<br />

mouse; 2) whether COX2 expression <strong>and</strong>/or <strong>activation</strong> by ATV is <strong>eNOS</strong>-, <strong>iNOS</strong> <strong>and</strong>/or<br />

NF B-dependent. Methods: Male C57BL/6 wild-type (WT), University <strong>of</strong> North<br />

Carol<strong>in</strong>a <strong>eNOS</strong> -/- , <strong>and</strong> <strong>iNOS</strong> -/- mice received ATV 10 mg/kg/d (ATV+) or water alone<br />

(ATV-) for 3 days. Mice underwent 30m<strong>in</strong> coronary artery occlusion <strong>and</strong> 4h <strong>of</strong><br />

reperfusion, or hearts were harvested <strong>and</strong> subjected to ELISA, immunoblott<strong>in</strong>g, biot<strong>in</strong><br />

switch <strong>and</strong> electrophoretic mobility shift assay (EMSA). Results: ATV reduced IS only<br />

<strong>in</strong> the WT mice. ATV <strong>in</strong>creased <strong>eNOS</strong>, P-<strong>eNOS</strong>, <strong>iNOS</strong> <strong>and</strong> COX2 levels, <strong>and</strong> activated<br />

NF B <strong>in</strong> WT mice. It also <strong>in</strong>creased myocardial COX2 activity. In <strong>eNOS</strong> -/- mice, ATV<br />

<strong>in</strong>creased COX2 expression, but not COX2 activity or <strong>iNOS</strong> expression. NF B was not<br />

activated by ATV <strong>in</strong> the <strong>eNOS</strong> -/- mice. In the <strong>iNOS</strong> -/- mice <strong>eNOS</strong> <strong>and</strong> P-<strong>eNOS</strong> levels were<br />

<strong>in</strong>creased, but not <strong>iNOS</strong> <strong>and</strong> COX2 levels; however, NF B was activated. Conclusions:<br />

Both <strong>eNOS</strong> <strong>and</strong> <strong>iNOS</strong> are essential for the IS-limit<strong>in</strong>g effect <strong>of</strong> ATV. Expression <strong>of</strong><br />

COX2 by ATV is <strong>iNOS</strong>- but not <strong>eNOS</strong>- or NF B dependent. Activation <strong>of</strong> COX2 is<br />

dependent on <strong>iNOS</strong>.<br />

Key words: <strong>eNOS</strong>, <strong>iNOS</strong>, COX2, NF B, atorvastat<strong>in</strong>, <strong>in</strong>farct size.<br />

Introduction<br />

Copyright Information<br />

Page 2 <strong>of</strong> 35

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!